ChemicalBook
Chinese english Germany Japanese Korea

Eptifibatide Produkt Beschreibung

Eptifibatide Struktur
188627-80-7
CAS-Nr.
188627-80-7
Englisch Name:
Eptifibatide
Synonyma:
Intrifiban;INTEGRELIN;Eptifibatide;Eptifibatide fandachem;Eptifibatide USP/EP/BP;Eptifibatide acetate salt;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDE BRIDGE, MPA1-CYS6);Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,{MPA}{HAR}GDWPC-NH2
CBNumber:
CB0416566
Summenformel:
C35H49N11O9S2
Molgewicht:
831.96
MOL-Datei:
188627-80-7.mol

Eptifibatide Eigenschaften

Dichte
1.60±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
pka
4.01±0.10(Predicted)
CAS Datenbank
188627-80-7

Sicherheit

Giftige Stoffe Daten 188627-80-7(Hazardous Substances Data)

Eptifibatide Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Eptifibatide was first launched in the US (1998) as Integrilin for the iv treatment of acute coronary syndrome, in particular for patients at risk for abrupt vessel closure during or after coronary angioplasty. It is a synthetic cyclic heptapeptide based on rattlesnake venom disintegrin peptides and containing the RGD sequence (arginyl-glycyl-aspartyl) involved in the adhesive function of platelets. It can be prepared by classical solid-phase peptide synthesis or by fragment synthesis in solution. Eptifibatide is a reversible antagonist of the glycoprotein llb/llla complex, a specific platelet adhesion receptor that plays a central role in the cascade of thrombus formation by allowing mediators such as fibrinogen or von Willbrand factor to cross-link adjacent platelets and to give rise to aggregation. In diverse animal experimental models of arterial thrombosis, treatment with Eptifibatide resulted in an enhanced lysis of occlusive thrombus and a restoration of arterial blood flow. In clinical trials involving patients with acute coronary syndromes, Eptifibatide demonstrated a significant decrease in the incidence of death or nonfatal myocardial infarction at 30 days. In other trials in patients undergoing percutaneous coronary intervention (PCI), it showed a positive trend. Eptifibatide has the advantage of being short acting, its antiplatelet effect being rapidly reversible.

Originator

Cor Therapeutics (US)

Verwenden

A Arginin-glycin-aspartat-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.

Definition

ChEBI: A synthetic homodetic cyclic peptide comprising Nalpha-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulf de bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/I Ia receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures.

Trademarks

Integrilin

Allgemeine Beschreibung

Eptifibatide (Integrilin) is a syntheticcyclic heptapeptide that acts as a GPIIb/IIIa receptor antagonist,thus causing inhibition of platelet aggregation. Itsstructure is based on the natural product barbourin, a peptideisolated from the venom of a pygmy rattlesnake (Sistrurusmilarud barbouri). As part of the structure, there is a sequenceRGD that can bind to the RGD receptor found onplatelets and block its ability to bind with fibrinogen. Thisagent is used in the treatment of unstable angina and for angioplasticcoronary interventions.

Mechanism of action

The drug is eliminated primarily via renal mechanisms as eptifibatide and deaminated eptifibatide. The clinical importance of eptifibatide and its benefits in comparison with other therapeutic agents used in the treatment of acute coronary syndromes and percutaneous coronary intervention have recently been reviewed by Curran and Keating

Clinical Use

Eptifibatide is a cyclic heptapeptide composed of six amino acids and one mercaptopropionyl residue. The cyclization is completed via a disulfide linkage between the cysteine and the mercaptopropionyl moieties. The lysine-glycine-aspartate component of eptifibatide is highly specific for the GPIIb/IIIa receptor, with low binding affinity, as indicated by the rapid dissociation constant. Because of this, eptifibatide is a reversible, parenterally administered antagonist of platelet aggregation.

Eptifibatide Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Eptifibatide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 184)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497
010-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Hangzhou Go Top Peptide Biotech
0571-88211921
sales1@gotopbio.com CHINA 2610 58
Henan DaKen Chemical CO.,LTD.
+86-371-66670886
info@dakenchem.com China 21032 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22607 55
Hangzhou FandaChem Co.,Ltd.
008615858145714
+86-571-56059825 fandachem@gmail.com CHINA 8882 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26734 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3623 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 29961 58
Chengdu Biopurify Phytochemicals Ltd.
18482058008 18080483897
maggie@biopurify.com CHINA 2712 58
GIHI CHEMICALS CO.,LIMITED
08657186217390
sales@gihichemicals.com CHINA 310 58

188627-80-7()Verwandte Suche:


  • Eptifibatide acetate salt
  • Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2, >99%
  • MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2
  • INTEGRELIN
  • Eptifibatide
  • N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
  • MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDE BRIDGE, MPA1-CYS6)
  • Intrifiban
  • N6-(AMinoiMinoMethyl)-N2-(3-Mercapto-1-oxopropyl)-L-lysylglycyl-L-.alpha.-aspartyl-L-tryptophyl-L-prolyl-L-cysteinaMide Cyclic (16)-Disulfide
  • 3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2
  • Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,{MPA}{HAR}GDWPC-NH2
  • L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1→6)-disulfide
  • Eptifibatide fandachem
  • Eptifibatide USP/EP/BP
  • 188627-80-7
  • C35H49N11O9S2
  • Intermediates & Fine Chemicals
  • Peptides
  • Pharmaceuticals
Copyright 2019 © ChemicalBook. All rights reserved